

<i>About the Authors</i>	<i>v</i>
<i>Preface</i>	<i>vii</i>
<i>Nonproprietary and Brand Names of Drugs in Text and Illustrations</i>	<i>xiii</i>
<i>Definition of Symbols</i>	<i>xix</i>

SECTION 1 BASIC CONSIDERATIONS 1

CHAPTER 1	Therapeutic Relevance	3
CHAPTER 2	Fundamental Concepts and Terminology	19

SECTION 2 EXPOSURE AND RESPONSE AFTER A SINGLE DOSE 51

CHAPTER 3	Kinetics Following an Intravenous Bolus Dose	53
CHAPTER 4	Membranes and Distribution	77
CHAPTER 5	Elimination	119
CHAPTER 6	Kinetics Following an Extravascular Dose	169
CHAPTER 7	Absorption	197
CHAPTER 8	Response	233

SECTION 3 THERAPEUTIC REGIMENS 265

CHAPTER 9	Therapeutic Window	267
CHAPTER 10	Constant-Rate Input	283
CHAPTER 11	Multiple-Dose Regimens	319

SECTION 4 INDIVIDUALIZATION 359

CHAPTER 12	Variability	361
CHAPTER 13	Genetics	393
CHAPTER 14	Age, Weight, and Gender	411
CHAPTER 15	Disease	443
CHAPTER 16	Nonlinearities	491
CHAPTER 17	Drug Interactions	531
CHAPTER 18	Initiating and Managing Therapy	577

SECTION 5 SUPPLEMENTAL TOPICS 611

CHAPTER 19	Distribution Kinetics	613
CHAPTER 20	Metabolites and Drug Response	657

CHAPTER 21	Protein Drugs	687
CHAPTER 22	Prediction and Refinement of Human Kinetics from In Vitro, Preclinical, and Early Clinical Data	731

APPENDICES

759

APPENDIX A	Assessment of <i>AUC</i>	759
APPENDIX B	Ionization and the pH Partition Hypothesis	763
APPENDIX C	Distribution of Drugs Extensively Bound to Plasma Proteins	767
APPENDIX D	Plasma-to-Blood Concentration Ratio	775
APPENDIX E	Well-Stirred Model of Hepatic Clearance	777
APPENDIX F	Absorption Kinetics	781
APPENDIX G	Wagner-Nelson Method	785
APPENDIX H	Mean Residence Time	789
APPENDIX I	Amount of Drug in Body on Accumulation to Plateau	795
APPENDIX J	Introduction to MS Excel Simulations	799
APPENDIX K	Answers to Study Problems	805

<i>Index</i>	903
--------------	-----